Molecular Profiling for Risk Stratification in Appendiceal Cancer
Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer
City of Hope Medical Center
400 participants
May 1, 2026
OBSERVATIONAL
Conditions
Summary
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.
Eligibility
Inclusion Criteria6
- Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.
- Availability of archived tumor tissue suitable for molecular profiling.
- Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.
- Availability of relevant clinicopathologic data.
- Availability of survival or follow-up information when applicable.
- Age 18 years or older at diagnosis or tissue collection.
Exclusion Criteria5
- Insufficient tissue quantity or quality for molecular profiling.
- Inadequate DNA or RNA quality for sequencing or molecular assay preparation.
- Missing essential clinicopathologic information required for analysis.
- Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.
- Patients who do not meet institutional review board or consent requirements, if applicable.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Archived tissue specimens undergo DNA methylation profiling to characterize tumor-associated methylation alterations and identify methylation-based molecular features associated with clinicopathologic variables and survival outcomes. The profiling is performed for research purposes only and does not assign treatment.
Archived tissue specimens undergo m6A methylated RNA immunoprecipitation sequencing with matched input RNA sequencing to quantify transcriptome-wide m6A enrichment. The resulting molecular data are used for subtype discovery, m6A score construction, reduced-panel development, and association with clinicopathologic and survival outcomes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07587268